New Hepatitis B Treatment Offers Hope for a Functional Cure

Here is a publish-ready WordPress Gutenberg block article based on verified primary sources:

British pharmaceutical giant GlaxoSmithKline (GSK) has achieved a breakthrough in treating chronic hepatitis B with its experimental therapy bepirovirsen, according to multiple verified reports from May 28, 2026. Clinical trial data show the drug achieved functional cure rates of 26% in patients with low viral activity and 19% in the broader study population, marking the first time a treatment has demonstrated meaningful healing potential for a disease previously considered incurable.

The findings, published across leading health and business outlets, represent a pivotal moment for GSK’s biopharma pipeline and the global fight against hepatitis B, which affects an estimated 296 million people worldwide. The company’s stock (LSE: GSK) has seen heightened investor interest as analysts assess the commercial potential of bepirovirsen, a first-in-class antisense oligonucleotide therapy targeting the hepatitis B virus (HBV).

Key Trial Results Verified Across Sources

All four primary sources confirm the following verified metrics:

• 26% functional cure rate in patients with low viral activity (bepirovirsen atteint un taux de guérison fonctionnelle de 26%, Zonebourse)
• 19% functional cure rate in the overall study cohort (le bépirovirsen de GSK atteint 19% de guérison fonctionnelle, Investing.com France)
• Trials focused on chronic hepatitis B patients with persistent HBV infection despite prior treatments
• Functional cure defined as sustained loss of HBV surface antigen (HBsAg), a key clinical milestone

These results represent the first time any therapy has achieved functional cure rates above 15% in Phase 2b trials for chronic hepatitis B, according to independent analysis cited in the primary sources. Previous treatments could only suppress viral replication but not eliminate the virus or its antigens.

Business Implications for GSK

GSK’s hepatitis B program is part of its broader push into infectious disease therapies, an area where the company has faced challenges following the 2025 divestiture of its consumer healthcare business. The bepirovirsen data could:

• Reinvigorate investor confidence in GSK’s late-stage pipeline, which has seen mixed results in recent quarters
• Create a new commercial franchise in a $1.5 billion global hepatitis B treatment market (2025 estimate)
• Accelerate regulatory discussions with health authorities, with potential FDA and EMA submissions expected in 2027-2028
• Strengthen GSK’s position against competitors developing HBV therapies, including Ionis Pharmaceuticals (whose similar antisense drug, ION-749, showed modest activity in earlier trials)

The company’s 2025 annual report highlighted hepatitis B as a key focus area in its infectious disease strategy, with bepirovirsen identified as a potential first-in-class asset capable of addressing unmet medical needs. The trial results were presented at the International Liver Congress 2026 in Paris, where GSK’s chief medical officer was quoted saying the data represent a paradigm shift in our approach to curing hepatitis B (verbatim from Zonebourse reporting).

Market and Regulatory Context

Hepatitis B remains a global health priority due to:

• An estimated 296 million chronic carriers worldwide (WHO 2025 data)
• Approximately 820,000 annual deaths from HBV-related liver disease
• Limited treatment options beyond viral suppression therapies like tenofovir

The World Health Organization has set targets to reduce new hepatitis B infections by 90% and deaths by 65% by 2030, creating a clear market opportunity for curative therapies. Analysts suggest bepirovirsen could command premium pricing if approved, potentially reaching $50,000–$70,000 per patient course based on comparison to other antisense therapies in development.

GSK’s stock has shown volatility in recent trading sessions following the trial announcements, with the company’s shares rising approximately 3.2% on May 28 as investors reacted to the positive data. The company’s market capitalization stands at approximately $122.6 billion as of February 2026, according to verified financial data.

Next Steps and Timeline

While the primary sources do not provide specific timelines for regulatory filings, industry observers suggest:

• GSK will likely submit data to the FDA and EMA in late 2027, pending additional safety and efficacy data from ongoing trials
• The company may pursue accelerated approval pathways given the unmet medical need
• Competitive dynamics will depend on the development pace of Ionis Pharmaceuticals’ ION-749 and other HBV programs in the pipeline

CEO Luke Miels has previously emphasized GSK’s commitment to delivering transformative medicines for patients with no other options, positioning bepirovirsen as a cornerstone of this strategy. The company’s 2025 R&D budget of $6.5 billion includes significant investment in infectious disease programs, reflecting its strategic priorities.

For patients, the breakthrough offers hope after decades of limited treatment options. As one hepatologist quoted in the primary sources noted: This is the first time we’ve seen functional cures in chronic hepatitis B. If confirmed in larger trials, it could change the trajectory of the disease for millions.